Skin Abnormalities: Clinical Trials

13 trials for Skin Abnormalities, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 unknown. 13 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Unknown 13
Phase 15Unknown 5

Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
ALLO-ASC-SHEET, Vehicle Control - Dystrophic Epidermolysis Bullosa
Phase 2UnknownAnterogen Co., Ltd.62023-05-012024-04-22
Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene
PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa
Phase 1 / Phase 2UnknownPhoenicis Therapeutics82023-04-302023-03-31
Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.
Dentoxol mouthrinse dosages - Epidermolysis Bullosa, Oral Ulcer
Phase 2UnknownUniversity of Chile1002022-04-062022-04-14
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62022-03-282023-09-21
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62021-10-192023-06-18
Optimizing IV Gentamicin in JEB
Gentamicin Sulfate, Injectable - Junctional Epidermolysis Bullosa
Phase 1 / Phase 2UnknownUniversity of Southern California62019-10-312022-11-03
Use of Propranolol Hydrochloride in the Treatment of Metastatic STS
Propranolol Hydrochloride, Doxorubicin - Malignant Soft Tissue Sarcoma
Phase 2UnknownAin Shams University502019-08-302018-02-23
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Gentamicin - Recessive Dystrophic Epidermolysis Bullosa
Phase 1 / Phase 2UnknownUniversity of Southern California92018-07-052022-11-03
Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa
mesenchymal stem cells derived from bone marrow (BM-MSCs) - Epidermolysis Bullosa Dystrophica, Recessive
Phase 1 / Phase 2UnknownInstituto de Investigación Hospital Universitario La Paz92018-05-172019-11-08
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Sirolimus 2%, Vehicle - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Phase 2UnknownPremier Specialists, Australia82016-05-012017-10-24
Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa
Mesenchymal stromal cells - Recessive Dystrophic Epidermolysis Bullosa
Phase 1 / Phase 2UnknownKing's College London102015-06-012017-03-03
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
Diacerin cream - Epidermolysis Bullosa Simplex
Phase 2UnknownTel-Aviv Sourasky Medical Center502015-06-012015-06-12
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
Dysport® (Botulinumtoxin A (Btx A)), Placebo - Epidermolysis Bullosa Simplex
Phase 2UnknownUppsala University402009-05-012011-03-09

Narrower conditions

Epidermolysis Bullosa Dystrophica (5)  ·  Epidermolysis Bullosa Simplex (3)  ·  Epidermolysis Bullosa (2)  ·  Xeroderma Pigmentosum (2)  ·  Epidermolysis Bullosa, Junctional (1)  ·  Ichthyosis, X-Linked (1)  ·  Oral Ulcer (1)

Broader conditions

Congenital Abnormalities (13)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13)  ·  Genetic Diseases, Inborn (13)  ·  Skin Diseases (13)  ·  Skin Diseases, Genetic (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Skin Diseases, Vesiculobullous (10)  ·  Epidermolysis Bullosa (8)  ·  Collagen Diseases (5)  ·  Connective Tissue Diseases (5)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)  ·  DNA Repair-Deficiency Disorders (2)  ·  Neoplasms (2)

Interventions

Gentamicins (2)  ·  afamelanotide (2)  ·  Doxorubicin (1)  ·  Gels (1)  ·  Injections (1)  ·  Propranolol (1)  ·  abobotulinumtoxinA (1)

Sponsors

Clinuvel Europe Limited (2)  ·  University of Southern California (2)  ·  Ain Shams University (1)  ·  Anterogen Co., Ltd. (1)  ·  Instituto de Investigación Hospital Universitario La Paz (1)  ·  King's College London (1)  ·  Phoenicis Therapeutics (1)  ·  Premier Specialists, Australia (1)  ·  Tel-Aviv Sourasky Medical Center (1)  ·  University of Chile (1)  ·  Uppsala University (1)

Countries

United States (4)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Chile (1)  ·  Germany (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Carl Swartling (1)  ·  David T. Woodley, MD (1)  ·  Dedee F Murrell, MD (1)  ·  Eli Sprecher, Prof. (1)  ·  Hal Landy, MD (1)  ·  John McGrath, FRCP/FSci/MD (1)  ·  Mei Chen, Ph.D (1)  ·  Mei Chen, PhD (1)  ·  Susanne Kramer, MsC (1)

Results publications

PMID 35234826, PMID 40268883, PMID 42164509